Yoshiki Hirooka

Prof. Dr. Yoshiki Hirooka

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YHYoshiki Hirooka
Yoshiki Hirooka
Hideki KasuyaHideki Kasuya
Hideki Kasuya
Takuya IshikawaTakuya Ishikawa
Takuya Ishikawa
HKHiroki Kawashima
Hiroki Kawashima
EOEizaburo Ohno
Eizaburo Ohno
HGHidemi Goto
Hidemi Goto
Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). HF10 is a spontaneously mutated oncolytic virus derived from a herpes simplex virus-1, and it has potential to show strong antitumor effect against malignancies without damaging normal tissue. We aimed to evaluate the safety and anti-tumor effectiveness in phase I dose-escalation trial of direct injection of HF10 into unresectable locally advanced pancreatic cancer under endoscopic ultrasound (EUS)-guidance in combination with erlotinib and gemcitabine administration. The mid-term results have been previously reported and here we report the final results of our study. This was a single arm, open-label Phase I trial. HF10 was injected once every 2 weeks and continued up to four times in total unless dose-limiting toxicity (DLT) appears. A total of nine subjects in three Cohorts with dose-escalation were planned to be enrolled in this trial. The primary endpoint was the safety assessment and the secondary endpoint was the efficacy assessment. Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6.3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR). HF10 direct injection under EUS-guidance in combination with erlotinib and gemcitabine was a safe treatment for locally advanced pancreatic cancer. Combination therapy of HF10 and chemotherapy should be explored further in large prospective studies. Trial registration: This study was prospectively registered in UMIN-CTR (UMIN000010150) on March 4th, 2013.


1 April 2009 in Pancreas
Verified
Journal Article
Closed access
YHYoshiki Hirooka
Yoshiki Hirooka
AIAkihiro Ito
Akihiro Ito
HKHiroki Kawashima
Hiroki Kawashima
KHKazuo WINDOW Hara Hara
Kazuo WINDOW Hara Hara
KNKoji Nonogaki
Koji Nonogaki
HGHidemi Goto
Hidemi Goto
Dendritic cell (DC) therapy frequently induces a measurable immune response. However clinical responses are seen in a minority of patients, presumably due to insufficient expansion of antigen-specific cytotoxic T lymphocytes (CTLs) capable of eradicating tumor cells. To increase therapeutic efficacy of DC-based vaccination, we have undertaken the first clinical trial involving a combination therapy of gemcitabine (GEM) with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Patients (n = 5) received the treatment course, which consisted of intravenous GEM administration at 1000 mg/m2 (day 1) and the endoscopic ultrasound-guided fine-needle injection of OK432-pulsed DCs into a tumor, followed by intravenous infusion of lymphokine-activated killer cells stimulated with anti-CD3 monoclonal antibody (CD3-LAKs) (day 4), at 2-week intervals. No serious treatment-related adverse events were observed during the study period. Three of the 5 patients demonstrated effective responses to this clinical trial; 1 had partial remission and 2 had long stable disease more than 6 months. In the patient with partial remission, it has been shown that DC-based vaccination combined with GEM administration induces tumor antigen-specific CTLs. This combined therapy was considered to be synergistically effective and may have a role in the therapy of pancreatic cancer for inducing tumor antigen-specific CTLs.

12 September 2013 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
YIYuya Itoh
Yuya Itoh
AIAkihiro Itoh
Akihiro Itoh
HKHiroki Kawashima
Hiroki Kawashima
EOEizaburo Ohno
Eizaburo Ohno
YNYosuke Nakamura
Yosuke Nakamura
YHYoshiki Hirooka
Yoshiki Hirooka

1 August 2012 in Pancreas
Verified
Journal Article
Closed access
EOEizaburo Ohno
Eizaburo Ohno
AIAkihiro Itoh
Akihiro Itoh
HKHiroki Kawashima
Hiroki Kawashima
TITakuya Ishikawa
Takuya Ishikawa
HMHiroshi Matsubara
Hiroshi Matsubara
YHYoshiki Hirooka
Yoshiki Hirooka
Objectives The natural history of branch duct–type intraductal papillary mucinous neoplasms (BD-IPMNs) of the pancreas remains unclear. We conducted a retrospective long-term follow-up study for malignant transformation (MT) of BD-IPMNs focusing on morphological changes. Methods The subjects consisted of 142 patients who underwent contrast-enhanced endoscopic ultrasonography for initial diagnosis from January 2001 with more than 12 months of follow-up. The MT rate, including the co-occurrence of invasive ductal cancer, was evaluated by univariate and multivariate analysis. In addition, on the basis of morphological changes in patients who underwent surgery, the predictive factors for malignant IPMNs were evaluated. Results Median follow-up term was 42.5 months (range, 12–105 months). Thirty patients who exhibited morphological changes underwent surgery. Malignant transformation occurred in 9 patients (6.3%), and 5-year MT rate was 10.7%. The co-occurrence of invasive ductal cancer was seen in 5 patients. Multivariate analysis showed that the existence of mural nodules at initial diagnosis and involvement of main pancreatic duct were significant predictors of MT of BD-IPMN. Conclusions Malignant transformation of BD-IPMN is not rare. The observation of morphological changes of main pancreatic duct and nodules, mainly on contrast-enhanced endoscopic ultrasonography, is practical and useful for predicting MT of BD-IPMN itself. Abbreviations IPMN - intraductal papillary mucinous neoplasm BD-IPMN - branch duct–type intraductal papillary mucinous neoplasm MT - malignant transformation IDC - invasive ductal cancer MPD - main pancreatic duct CE-EUS - contrast-enhanced endoscopic ultrasonography EUS-FNA - endoscopic ultrasonography–guided fine needle aspiration MD-IPMN - main duct–type intraductal papillary mucinous neoplasm MD-CT - multidetector row computed tomography HR - hazard ratio OR - odds ratio

8 October 2014 in Journal of Medical Ultrasonics
Verified
Journal Article
Closed access
PDF file
YHYoshiki Hirooka
Yoshiki Hirooka
TKTakamichi Kuwahara
Takamichi Kuwahara
AIAtsushi Irisawa
Atsushi Irisawa
FIFumihide Itokawa
Fumihide Itokawa
HUHiroki Uchida
Hiroki Uchida
TSTsuyoshi Shiina
Tsuyoshi Shiina